 is that because we had only the current endpoint, we didn't see a way to show that our new innovative therapy was better than the current therapy. And the current therapy is relatively inexpensive, and it's available generically. So the company didn't see a way to have an adequate return on investment and saw better commercial value actually taking it into autoimmune diseases like rheumatoid arthritis.